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Abstract 
Background: The number of patients undergoing shock wave lithotripsy (SWL) for kidney stones is increasing annu‑
ally, and as such the development of post‑operative complications, such as haematuria and acute kidney injury (AKI) 
following SWL, is likely to increase. The aim of the study was to evaluate changes in routine blood and novel biomark‑
ers following SWL, for the treatment of kidney stones.
Methods: Twelve patients undergoing SWL for solitary unilateral kidney stones were recruited. From patients (8 
males and 4 females) aged between 31 and 72 years (median 43 years), venous blood samples were collected pre‑
operatively (baseline), at 30, 120 and 240 min post‑operatively. Routine blood tests were performed using a Sysmex 
XE‑5000, and Beckman Coulter AU5800 and AU680 analysers. NGAL, IL‑18, IL‑6, TNF‑α, IL‑10 and IL‑8 concentrations 
were determined using commercially available ELISA kits.
Results: Significant (p ≤ 0.05) changes were observed in several blood parameters following SWL. NGAL concentra‑
tion significantly increased, with values peaking at 30 min post‑treatment (p = 0.033). Although IL‑18 concentration 
increased, these changes were not significant (p = 0.116). IL‑6 revealed a statistically significant rise from pre‑operative 
up to 4 h post‑operatively (p < 0.001), whilst TNF‑α significantly increased, peaking at 30 min post‑SWL (p = 0.05). 
There were no significant changes to IL‑10 and IL‑8 concentrations post‑SWL (p > 0.05).
Conclusions: Changes to routine blood tests and specific biomarkers, in the future, may be more useful for clinicians. 
In turn, identification of a panel of biomarkers could provide valuable data on “normal” physiological response after 
lithotripsy. Ultimately, studies could be expanded to identify or predict those patients at increased risk of developing 
post‑operative complications, such as acute kidney injury or. These studies, however, need validating involving larger 
cohorts.
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Background
Kidney stones are becoming an increasing clinical and 
economic burden on global health services [1]. Shock 
wave lithotripsy (SWL) allows a non-invasive treatment 
of kidney stones smaller than 2 cm [2]. Recent evidence 
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frequently, as there has been a 2/3 increase in the preva-
lence of kidney stones in the UK over a 10-year period 
[3].
Despite the use of radiological imaging to accurately 
direct shock waves to the location of the kidney stone, 
there is still a risk of localised complications associ-
ated with SWL [4]. The most common SWL-associated 
injury is primary vascular haemorrhage [5]. Originally, it 
was thought that the prevalence of renal haematoma in 
patients post-operatively was < 1%, however, it was later 
discovered that 29% of patients developed haematomas 
post-SWL [5, 6]. Renal trauma also results in an inflam-
matory response that initiates tissue remodelling and 
can result in the production of scar tissue [7]. Research 
has shown that dose-dependant renal fibrosis occurred 
in canine subjects undergoing SWL [8]. Fibrosis of renal 
tissue can result in a partial or complete loss of func-
tion to the affected area. One study reports that ~ 10% 
of SWL patient can experience a urinary tract infec-
tion after treatment [9]. The overall complication rate, 
according to CROES URS study, was up to 25%, which 
included haemorrhage, pyrexia, urine infection (UTI), 
acute kidney injury (AKI) and sepsis as the most com-
mon post-operative complications [10]. However, other 
potentially devastating injuries following SWL have been 
reported, including acute pancreatitis, splenic rupture, 
bowel injury with perforation, myocardial infarction, and 
rupture of abdominal aortic aneurysms [11–14]. In addi-
tion, it is expected that there will be a greater incidence, 
more recurrent episodes and overall higher number of 
patients having SWL. Subsequently, the complication 
rate is likely to increase, especially with an aging society. 
As such, it may be advantageous to identify patients who 
are at increased risk of developing complications follow-
ing SWL.
Current practice provides little, if any, knowledge 
regarding identifying, or predicting, those patients at 
increased chance of complications. Novel biological 
parameters have the potential to identify complications 
such as bleeding, acute kidney injury and infection, 
which may arise following SWL. Importantly, to date, 
there is limited research evaluating the pathophysiologi-
cal effects of SWL on clinical outcome measures. Cru-
cially, at present, there are minimal studies that have 
reported the impact of SWL on novel biomarkers such as 
NGAL, IL-18, IL-6, TNF-α, IL-10 and IL-8.
Previously, our group have published outcomes of 
haemostatic function following SWL and other opera-
tive surgeries, and this may provide a good foundation to 
undertake larger studies that may ultimately determine 
which patients are at increased risk of haemorrhage fol-
lowing surgeries [15–18]. Moyes et al. [19] documented 
that changes to several biochemical and haematological 
parameters occur following flexible ureteroscopy (FURS), 
for the removal of kidney stones. Specifically, FURS is an 
invasive procedure employed for the treatment of stone 
disease. During this study, 4 patients from 40 developed 
post-operative complications, which resulted in sig-
nificant changes to several of the routine biochemical 
and haematological blood tests. The information pro-
vided in this paper, in turn, highlights the need and the 
importance to undertake further research in this area, 
and to fully understand the ‘normal’ response to these 
treatments.
Neutrophil gelatinase-associated lipocalin (NGAL) is 
a protein that is bound to matrix metalloproteinase-9 
(MMP-9) in neutrophils [20]. NGAL is generally found 
in low concentrations in human tissue, but is significantly 
increased in cases of trauma to kidney, colon, liver and 
lung tissue [21]. Originally identified as a component of 
neutrophil granules, it has since been found to be pro-
duced by tissues undergoing inflammation [22]. It has 
been shown in patients with chronic kidney disease 
(CKD) that NGAL concentrations correlate with the 
severity of renal impairment; however, it has been found 
that NGAL concentrations are much higher in patients 
with AKI compared with CKD [20, 21]. The upregulation 
of NGAL during AKI, may therefore provide a specific 
novel biomarker following SWL, which may help predict 
or identify an abnormal response to treatment, such as 
AKI.
Cytokine-mediated inflammation has been implicated 
in the pathogenesis of AKI and chronic kidney CKD, 
where endothelial and tissue injuries are associated with 
the release of specific mediators that may initiate the 
inflammatory cascade [23, 24]. Interleukin 18 (IL-18) is 
a pro-inflammatory cytokine, which is upregulated dur-
ing an inflammatory response. The majority of IL-18 
expressed is from activated macrophages; however, IL-18 
has also been shown to be expressed in renal tubular epi-
thelial cells [25]. Urine IL-18 concentrations have been 
found to be significantly raised in patients with AKI com-
pared to those with urinary tract infection, chronic renal 
insufficiency and nephrotic syndrome [26]. This demon-
strates that IL-18 is upregulated in cases of AKI rather 
than CKD, making it a possible biomarker for the identi-
fication of acute injuries following SWL.
Interleukin-6 (IL 6) is a typical example of a multifunc-
tional cytokine involved in the regulation of the immune 
response, haematopoiesis, and inflammation. Raised 
serum levels of IL-6 have been associated with sepsis in 
AKI patients [23, 24]. One of the principal acute-phase 
cytokines produced by monocytes and macrophages in 
response to infection is tumour necrosis factor-alpha 
(TNF-α). TNF-α has a complex and extensive repertoire 
of functions within the inflammatory cascade system 
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[27]. Increased levels of TNF-α are thought to poten-
tially prime and therefore elicit a more rapid and promi-
nent response from neutrophils during the inflammatory 
process and may therefore be appreciated to be a noble 
biomarker for evaluating sustained inflammation or pre-
dicting complications [28].
Predominantly, interleukin-8 (IL-8) is a cytokine, 
comes from leukocytes and many types of cellular tis-
sues. Neutrophils are a major specific target for IL-8 
action. IL-8 is routinely being used as a marker for vari-
ous clinical conditions and is associated with chronic dis-
eases, infections and inflammation [29, 30]. IL-8 has also 
been reported to be detected in the urine of patients with 
several inflammatory renal disorders including pyelone-
phritis, haemolytic uraemic syndrome, graft rejection 
and various forms of glomerulonephritis [31].
IL-10 levels appear to have been overlooked in urology 
studies, with information regarding this biomarker and 
its relation to kidney damage being vague. IL-10 has been 
reported to play an integral role with respect to infec-
tion, as well as inflammation, due to its anti-inflamma-
tory effect [30]. However, as previously mentioned this 
cytokine is also affected by many other factors. Serum, 
peritoneal fluid and saliva levels of IL-10 are known to 
be elevated in conditions such as infections, melanoma, 
tumours, and autoimmune diseases [32, 33].
As highlighted above, studies involving cytokines in 
various clinical settings have been well documented. 
However, with respect to urology, there are limited stud-
ies evaluating the role of cytokines following kidney stone 
treatment and are therefore worthy of investigation.
We aimed to evaluate changes in routine haematologi-
cal and biochemical blood tests, including novel biologi-
cal parameters, namely NGAL, IL-18, IL-6, TNF-α, IL-10 
and IL-8. This should allow us to understand better, the 
postoperative biological pathway following SWL, in kid-
ney stone management. This pilot-study has the potential 
to add a significant body of work to the literature, as well 
as providing the biological basis for future multi-centre 
studies.
Methods
Subject volunteers and shock wave lithotripsy (SWL)
Following ethical approval (Integrated Research Applica-
tion System REC 4:12/WA0117), and written informed 
consent, we recruited 12 patients who underwent SWL 
for kidney stone treatment. Of these, 8 were male, and the 
remaining 4 were female. The median age was 43  years 
(range 31 to 72). Using standard hospital protocol, SWL 
therapy was delivered with Wolf P3000 lithotripter, 
incorporating triple focus technology, and ultrasound/
fluoroscopic imaging was used for localisation.
Blood samples
Baseline (control) samples of venous blood were taken 
before SWL, using a cannula inserted into the ante-
cubital fossa for each patient. Subsequent sampling was 
undertaken at 30, 120 and 240  min post-operatively. 
Trained healthcare staff were present throughout the 
study period ensuring that blood samples were collected 
at the specific time-points. Vacutainers containing di-
potassium ethylene diamine tetra-acetic acid (EDTA) 
were used for sample collection. Plasma was obtained by 
centrifugation at 1000g for 15 min. Plasma was removed 
from the vacutainer and stored in aliquot tubes at − 80 °C 
until required for analysis.
An 87.5% compliance was obtained regarding blood 
sample collection. Participants 2, 7 and 10 (12.5% of the 
total participants) were unable to provide blood samples 
at 120 and 240 min post-operatively due to difficulty (i.e. 
poor veins) with the venesection.
Measurement of haematological and biochemical 
parameters
Full blood count (FBC) was undertaken via a Sysmex 
XE-5000 automated cell counter, and biochemistry tests 
undertaken using the Beckman Coulter AU5800 and 
AU680 analysers.
Measurement of NGAL, IL‑18, IL‑6, TNF‑α, L‑10 and IL‑8 
concentrations
Commercially available Human  Quantikine® ELISA 
kits for NGAL, IL-18, IL-6, TNF-α, IL-10 and IL-8 were 
purchased from R&D  Systems® catalogue numbers: 
DLCN20, 7620, D6050, DTA00C, D1000B and D8000C, 
respectively. All assays were run as per manufacturer’s 
instructions, in duplicate, with sample analysis being 
undertaken when enough patients were recruited on to 
the study to run a single 96-well assay plate (n = 3 plates 
per biomarker). Intra-assay % coefficient of variabil-
ity (CV) levels are reported, with a CV of < 10% being 
acceptable, ensuring assay precision and high perfor-
mance. Biomarker assay specifications are illustrated in 
Table 1.
Statistical analysis
Statistical analysis was carried out using SPSS (latest 
version). Initial testing for normality was carried out, 
and where data were parametric, repeated measures 
analysis of variance (ANOVA) between samples test 
was employed, adopting a 5% level of significance. Post 
hoc testing was conducted using the Bonferroni test for 
pairwise comparisons between means. Data that did not 
comply with normality were analysed using the Fried-
man test. Where the Friedman test resulted in statistical 
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significance, subsequent tests were performed using 
the Wilcoxon test. Statistical significance was accepted 
when p ≤ 0.05. All parametric data are presented as 
mean ± standard deviation (SD), whilst non-parametric 
results are presented as median ± interquartile range 




Haematological changes following SWL are presented in 
Table  2. The following biomarkers exhibited statistically 
significant decreases: basophils (p = 0.041), haemoglobin 
(p = 0.002), red blood cells (p = 0.001), and packed cell 
volume (p = 0.002). Furthermore, significant increases 
were seen in white blood cell (WBC) levels (p = 0.009), 
neutrophils (p = 0.017), monocytes (p = 0.003) and mean 
corpuscular haemoglobin (p = 0.047). No changes were 
reported in lymphocytes, eosinophils, mean cell vol-
ume, and mean corpuscular haemoglobin concentration 
(p > 0.05).
Biochemistry blood results
Biochemical changes following SWL are presented 
in Table  3. The following exhibited statistically sig-
nificant decreases: total protein (p = < 0.001), albumin 
(p = < 0.001), globulin (p = 0.006), alkaline phosphatase 
(p = 0.018) and sodium (p = 0.01). Furthermore, sig-
nificant increases were seen in alkaline transaminase 
(p = 0.01). No changes were reported in CRP, total biliru-
bin, urea, creatinine, and potassium (p > 0.05).
Novel biomarkers blood results
NGAL
Plasma NGAL concentration increased from baseline 
(pre-operative) (127.3 ± 87.4/166.8) and peaked at 30 min 
Table 1 Biomarker assay specifications
Biomarker ELISA assay Assay range (limits of detection) Sensitivity Specificity
NGAL 0.2–10 ng/ml 0.04 ng/ml Natural and recombinant human lipocalin‑2
IL‑18 26.6–1700 pg/ml 7.52 pg/ml Natural and recombinant human total IL‑18
IL‑6 3.1–300 pg/ml 0.7 pg/ml Natural and recombinant human IL‑6
TNF‑α 15.6–1000 pg/ml 5.5 pg/ml Natural and recombinant human TNF‑alpha
IL‑10 7.8–500 pg/ml 3.9 pg/ml Natural and recombinant human IL‑10
IL‑8 31.2–2000 pg/ml 7.5 pg/ml Natural and recombinant human IL‑8
Table 2 Haematological changes following SWL (n = 12)
Statistical significance following post hoc analysis is represented when *p ≤ 0.05. (M, male; F, female)
Baseline 30 min 120 min 240 min Reference range p value Statistical test
White blood cells 
(× 109/L)
5.7 (± 4.3/10.10) 7.15 (± 5.2/11.4)* 5.8 (± 5.10/14.2) 8.0 (± 3.9
5.5/14.50)*
4.0–11.0 0.009 Friedman
Neutrophils (× 109/L) 3.6 (± 2.4/7.4) 4.05 (± 2.9/8.60) 3.8 (± 2.90/11.90) 5.2 (± 3.4/11.2)* 1.7–7.5 0.017 Friedman
Lymphocytes 
(× 109/L)
1.6(± 1.3/3.6) 1.85 (± 1.3/3.1) 1.50 (± 1.0/2.2) 2.0 ± (1.0/3.0) 1.0–4.5 0.063 Friedman
Eosinophil (× 109/L) 0.1 (± 0.05/0.4) 0.1 (± 0.02/0.5) 0.1 (± 0.03/0.2) 0.1 (± 0.03/0.3) 0.0–0.4 0.101 Friedman
Basophils (× 109/L) 0.025 (± 0.01/0.6) 0.025 ± (0.01/0.6) 0.02 (± 0.01/0.03) 0.02 (± 0.01/0.07) 0.0–0.1 0.041 Friedman
Monocytes (× 109/L) 0.5 (± 0.3/0.6) 0.5 (± 0.4/0.8) 0.4 (± 0.3/0.8) 0.8 (± 0.5/1.0)* 0.2–0.8 0.003 Friedman
Haemoglobin (g/L) 124.5 (± 123/152) 117.5 (± 120/151)* 124 (± 120/141)* 120 ± (117/141)* M: 130–180
F: 115–165
0.002 Friedman
Red blood cells 
(× 109/L)





28.83 (± 25.4/31.7) 29.1 (± 26.6/32.4)* 29.4 (± 28.7/32.4)* 29.4 (± 27.7/32.1) 27.0–32.0 0.047 Friedman
Mean cell volume (fl) 87.3 (± 32.0/106.6) 87.9 (± 32.2/106.2) 88.7 (± 79.6/106.4) 88.7 (± 81.0/105.8) 80.0–100.0 0.404 Friedman
Packed cell volume 
(L/L)






34.02 ± 1.65 33.95 ± 1.23 34.27 ± 1.12 33.68 ± 0.83 32–36 0.179 ANOVA
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(195.1 ± 75.4/249.5) post-SWL (Fig.  1). At 120  min 
(163.4 ± 102.5/190.1) and 240  min (135 ± 71.1/163.1) 
NGAL concentration decreased towards basal levels. 
According to the Friedman test, there were statistically 
significant rises in NGAL following SWL (p = 0.033). 
Upon further post hoc testing no other changes were 
observed from baseline to individual time-points 
(p > 0.05).
IL‑18
Mean concentrations of plasma IL-18 increased from 
the baseline (pre-operatively) (310 ± 79.3) and peaked at 
the initial post-operative sampling of 30 min post-oper-
atively (417.5 ± 168.9) (Fig.  2). Mean concentrations of 
IL-18 were consistently raised with only slight changes 
at 120 min (378.2 ± 160) and 240 min (393 ± 181.2). Col-
lectively, there was no significant difference in IL-18 
Table 3 Biochemical changes following SWL (n = 12)
Statistical significance following post hoc analysis is represented when *p ≤ 0.05. (M, male; F, female)
Baseline 30 min 120 min 240 min Reference range p value Statistical test
CRP (mg/L) 3.1 (± 1.0/8.0) 1.65 (± 1.0/7.0) 1.8 (± 1.0/7.5) 1.9 (± 1.0/6.40) 0–5.0 0.101 Friedman
Total protein (g/L) 71.33 ± 4.83 67.93 ± 4.23* 64.45 ± 3.45* 67.64 ± 3.03* 60.0–80.0 < 0.001 ANOVA
Albumin (g/L) 43.13 ± 3.0 40.90 ± 3.12* 39.33 ± 3.5* 40.77 ± 3.22 35.0–45.0 < 0.001 ANOVA
Globulin (g/L) 28 (± 25/37) 28 (± 22/30) 26 (± 23/27)* 26.5 (± 25/30) 23.0–35.0 0.006 Friedman
Total bilirubin (µmol/L) 13.5 (± 7/23) 15 (± 7/22) 12 (± 9/43) 11 (± 8/22) < 21 0.140 Friedman
Alkaline phosphatase—ALP 
(U/L)
73 (± 36/91) 65 (± 37/93)* 68.5 (± 35/85)* 72.5 (± 34/86) 30.0–130.0 0.018 Friedman
Alkaline transaminase—ALT 
(U/L)
35.5 (± 18/70) 34 (± 18/65) 35 (± 17/62) 37 (± 15/67)* < 41 (male)
< 33 (female)
0.01 Friedman
Urea (mmol/L) 4.90 (± 2.7/6.0) 4.80 (± 2.8/6.0) 4.90 (± 3.6/5.20) 4.85 (± 3.30/5.20) 2.5–7.8 0.478 Friedman
Creatinine (µmol/L) 67.1 (± 11.39) 69.7 (± 13.04) 73.0 (± 12.30) 71.1(± 14.09) M: 58.0–110.0
F: 46.0–92.0
0.365 ANOVA
Sodium (mmol/L) 140 (± 135/140) 139 (± 132/143)* 137 (± 134/142)* 138 (± 133/140)* 135.0–146.0 0.010 Friedman


























Fig. 1 The effect of SWL, for the treatment of kidney stones, on NGAL concentration. Data points expressed as median ± IQR. p = 0.033 as 
determined by Friedman test. The intra‑assay CV was 4.8%. Patient samples were diluted 1 in 60 as per manufacturer guides
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(p = 0.116), as determined by ANOVA. Although not sta-
tistically significant, there was a trend of increasing IL-18 
concentration up to 4 h post-SWL.
IL‑6
Following SWL, IL-6 levels increased across all 
time-points. Specifically, IL-6 increased from base-
line (pre-operative) (2.40 ± 1.19/2.47), during 30  min 
(3.94 ± 2.3/4.5), 120  min (6.37 ± 4.6/8.8) and 240  min 
(8.05 ± 6.6/9.5) post-operatively (Fig.  3). Statistical sig-
nificance was determined using the Friedman test 
(p < 0.01). Upon further testing using the Wilcoxon test 
a statistically significant difference was shown between 
the baseline value and 120 min, 240 min post-operatively 
(p = 0.013, p = 0.05, respectively).
TNF‑α
Following SWL, TNF-α levels increased from base-
line (pre-operative) (1.592 ± 0.26/4.75) and peaking at 
30  min post-operatively (2.18 ± 0.67/2.18). At 120  min 
(1.54 ± 0.39/3.69) and 240  min (1.33 ± 0.3/3.56) TNF-α 
concentrations decreased (Fig. 4). Statistical significance 
was determined using the Friedman test (p = 0.05). Upon 
further testing using the Wilcoxon test, significant differ-
ence was shown between baseline value and 30 min post-
operatively (p = 0.041).
IL‑10
Following SWL no significant changes were seen 
in IL-10 concentration, p= 0.086 as determined by 
the Friedman test (Fig.  5). Although no significant 
changes were observed, IL-10 concentrations slightly 
increased from baseline (6.43 ± 3.7/7.0), peaking at 
30  min (6.72 ± 3.8/7.2) post-operatively. Following 120 
(4.6 ± 2.2/4.7) and 240  min (5.65 ± 3.5/6.1) postopera-
tively levels decreased.
IL‑8
Following SWL, no significant changes were seen in IL-8 
concentrations, p = 0.187 as determined by the Friedman 
test (Fig.  6). Although non-significant, IL-8 concentra-
tions slightly increased from baseline (13.58 ± 7.3/16.8) 
at 30  min (13.65 ± 7.5/18.7) and decreased there-
after at 120  min (11.63 ± 7.3/13.8), and at 240  min 
(12.94 ± 7.6/14.1) post-operatively.
Discussion
The aim of this study was to investigate the effects of 
SWL, for the treatment of kidney stones, on routine 
blood tests, and specific biomarkers, namely NGAL, 
IL-18, IL-6, IL-10 and IL-8. Interestingly, in the current 
study, no post-operative complications were reported. As 
SWL is considered a relatively minimally invasive proce-























Fig. 2 The effect of SWL, for the treatment of kidney stones, on IL‑18 concentration. Data points expressed as mean ± standard deviation. p = 0.89 
as determined by a repeated measures ANOVA. The intra‑assay CV was 5.1%
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be appreciated that the reported outcomes are directly 
relatable to the procedure. It can therefore be appreciated 
that this prospective feasibility study provides crucially 
important information on “normal” physiological out-
comes after SWL.
With regard to routine blood tests, significant 



























Fig. 3 The effect of SWL, for the treatment of kidney stones, on IL‑6 concentration. Data points expressed as median ± IQR. p < 0.001 as determined 
























Fig. 4 The effect of SWL, for the treatment of kidney stones, on TNF‑α concentration. Data points expressed as median ± IQRr. p = 0.05 as 
determined by Friedman test. The intra‑assay CV was 6.5%
Page 8 of 11Hughes et al. Eur J Med Res           (2020) 25:18 
parameters were observed following SWL. Interest-
ingly, our findings are like those occurring after other 
minimally invasive urological surgery for the treatment 
of kidney stones [19]. In the present study, specifi-
cally, total leukocyte (white blood cells), neutrophils, 
erythrocytes (red blood cells) and haemoglobin con-
centrations, increased and decreased, respectively; 
whilst significant decreases in total protein, albumin, 
























Fig. 5 The effect of SWL, for the treatment of kidney stones, on IL‑10 concentration. Data points expressed as median ± IQRr. p = 0.086 as 
























Fig. 6 The effect of SWL, for the treatment of kidney stones, on IL‑8 concentration. Data points expressed as median ± IQRr. p = 0.187 as 
determined by Friedman test. The intra‑assay CV was 5.1%
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Changes to haematological markers following upper 
and lower limb orthopaedic surgical procedures have 
been reported by others [16, 17]. However, little is known 
about the role of routine biochemical and haematologi-
cal blood tests following SWL. Hughes et  al. [15] have 
previously reported changes to fibrinogen and vWF 
(haemostatic function markers), that may help identify 
and subsequently predict patients at increased risk of 
bleeding complications following SWL. Similar observa-
tions were reported by Wozniak et al. [18], where it was 
proposed that oxidative stress may result in haemostatic 
changes in kidney stone patients, both prior to and espe-
cially after SWL, suggesting that SWL modulates haemo-
stasis, and may contribute to coagulopathy episodes that 
can occur in high-risk patients following SWL.
In addition to the routine blood test results, biomarkers 
such as NGAL, IL-6 and TNF-α significantly increased 
following SWL, with the most noticeable changes occur-
ring at 30  min post-operatively for most biomarkers. 
Devarajan [21] has reported that NGAL provides an 
excellent biomarker for the early diagnosis of AKI, and 
for the prediction of clinical outcomes and mortality in 
several common clinical circumstances. Biologically, 
it can be appreciated that during SWL, high stresses 
are placed on the kidney, which may result in AKI, and 
subsequent impairment of renal function. Serum cre-
atinine has long been considered a biomarker of choice 
for AKI, although not sensitive and is unreliable. With 
regard to our present study, creatinine levels increased 
beyond 2 h post-SWL, whereas NGAL peaked at 30 min 
and returned towards basal levels between 2 and 4 h. It 
may therefore be proposed that any sustained increased 
changes to NGAL may provide a reliable marker for iden-
tifying and subsequently monitoring AKI following SWL.
Although there are many variables that can influence 
NGAL concentration within blood, such as GFR and 
formation of the biological agent by other cells such as 
neutrophils, it is important to remember that NGAL is 
not specific in diagnosing the aetiology of renal impair-
ment, but may apply a crude method of indicating some 
sort of underlying pathology that needs to be clinically 
addressed [21, 34, 35]. It could therefore be appreciated 
that NGAL could act as an indicator, upon which fur-
ther investigations, including medical imaging, analysis 
of a panel of biomarkers are undertaken to reveal the full 
extent of the complications.
With regard to IL-18, Faust et al. [25] and Parikh et al. 
[26] demonstrated that this pro-inflammatory cytokine is 
expressed in renal tubular epithelial cells, and urine lev-
els of IL-18 have been reported to be raised in AKI com-
pared to those with other co-morbidities, such as urinary 
tract infection. Although no significant changes were 
observed in IL-18 concentration following SWL in the 
present study, trends of increasing levels were reported, 
highlighting the need to undertake further studies involv-
ing larger cohorts into this novel biological parameter.
Previous studies have reported of raised serum IL-6 
levels being associated with sepsis in AKI patients [23, 
24]. Our study reports a similar pattern of increasing 
IL-6 following SWL. Although one can appreciate that 
further investigations involving a larger cohort would 
be required, IL-6 may potentially provide an additional 
biomarker screening tool for predicting the severity of 
AKI and subsequent urosepsis that may develop in high-
risk patients following lithotripsy. A similar pattern of 
increasing TNF-α concentration was observed following 
SWL, which affirms along with other studies the inte-
gral role that this cytokine plays during an inflammatory 
response [27, 28]. Although no significant changes were 
observed in IL-10 and IL-8, trends of increasing concen-
trations were observed in the present study. These find-
ings agree with others who have demonstrated increased 
levels in various clinical settings [30, 32, 36].
To date, little is known about the effect of SWL on rou-
tine blood tests and novel biomarkers. This pilot-study, 
we believe, has contributed to the literature, as well as 
providing the biological basis for future multi-centre 
studies. We have shown that changes to several biochem-
ical and haematological (routine) blood tests, includ-
ing specific biomarkers, such as NGAL, occur following 
SWL. It is hypothesised that if larger multi-centre cohort 
studies reproduce these findings, then these biomarkers 
(or probably a panel of biomarkers) may potentially pro-
vide clinicians with a better understanding of the “nor-
mal” physiological response following SWL, and thus 
may allow changes in clinical protocols for patient man-
agement. For example, any sustained changes to selective 
biomarkers, may provide clinically useful information, 
such as identifying or predicting the development of 
infection or significant bleeding episodes following SWL 
[13, 15–17].
Clearly, the weaknesses of this study include patient 
numbers which have been recruited thus far (n = 12), 
subsequent blood sampling opportunities beyond 4  h, 
and the use of controls. Although the numbers are 
small, it was designed as a pilot study, and as such, we 
feel that we have provided a scientific basis to assess 
these biomarkers and their correlation with clinical 
outcome, in a larger multi-centre cohort study. Logisti-
cally, it was very difficult to retain patients beyond 4 h, 
as SWL was carried out as a strict day case treatment. 
Our current ethical approval did not allow SWL to be 
performed with normal healthy individuals (e.g. control 
patients, without kidney stones), but in future stud-
ies we could compare SWL with kidney stone patients 
undergoing other minimally invasive therapies. This 
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approach could also allow us to identify and establish 
the “normal” post-operative physiological response 
after urological treatment.
Conclusion
Changes to routine blood tests and specific biomark-
ers, in the future, may be more useful for clinicians. In 
turn, identification of a panel of biomarkers could pro-
vide valuable data on “normal” physiological response 
after lithotripsy. Ultimately, studies could be expanded 
to identify or predict those patients at increased risk of 
developing post-operative complications, such as acute 
kidney injury or. These studies, however, need validat-
ing involving larger cohorts.
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